Basic Information


GTO ID GTC0709
Trial ID ACTRN12613000198729
Disease Metastatic Melanoma
Altered gene GD2
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment GD2 CAR-T cells
Generation3rd
PhasePhase1
Recruitment statusActive, Not Recruiting
TitleStudy of increasing doses of genetically modified GD2-specific T cells in patients with metastatic melanoma and refractory solid tumours
Year2013
CountryAustralia
Company sponsorRoyal Adelaide Hospital Cancer Centre

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 1E7 cells/m^2, 2E7 cells/m^2, 1E8 cells/m^2
Donor type Autologous
Pts 12
Age Adult, Older_Adult
Lymph depletion No
References DOI: 10.1158/1538-7445.AM2019-CT118

Relationship Graph

Overview of Knowledge Graph